Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Navigerad Repetitiv TMS för Kronisk Tinnitus

18 september 2026 uppdaterad av: National University Hospital, Singapore

Neuronavigerad transkraniell magnetstimulering som ett kompletterande behandlingsalternativ vid kronisk tinnitus

This study is testing whether a special type of brain stimulation called neuronavigated TMS can help reduce tinnitus (ringing in the ears). 50 people with tinnitus will each receive 20 treatment sessions - 10 real treatments and 10 sham treatments in random order, with a 2-week break between them. Before starting, participants get an MRI brain scan to guide where the stimulation device is placed. Questionnaires of measuring tinnitus severity will be asked four times throughout the study to determine to check the effect of TMS on treating tinnitus.

Studieöversikt

Status

Upphängd

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study aims to investigate the beneficial effects of neuronavigated TMS (nTMS) in alleviating tinnitus symptoms and to establish safety and tolerability of nTMS in patients with tinnitus.

50 eligible subjects will be recruited and be randomized to receive 10 sessions of daily verum nTMS followed by 10 sessions of daily sham nTMS (verum-sham), or sham nTMS followed by verum nTMS (sham-verum). There will be a 2-week break between the two types of nTMS.

MRI will be conducted before the 1st session of nTMS for the TMS navigation system.

Outcome measures include Tinnitus Handicap Inventory (THI), Tinnitus Functional Index (TFI), and Tinnitus-Visual Analogue Scale (T-VAS). All assessment will be evaluated 4 times- before the 1st nTMS session, after the 10th nTMS session, before the 11th nTMS and after the 20th nTMS session.

Studietyp

Interventionell

Inskrivning (Beräknad)

50

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Singapore, Singapore
        • Alexandra Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age 21-80 years old;
  2. Subjective tinnitus severity as per Tinnitus-Visual Analogue Scale of 1/10 and above (in any domain: sound, distress, Quality of Life)

Exclusion Criteria:

  1. Pregnancy;
  2. Any metal implants inside the body that are contraindications of MRI scan;
  3. Cardiac pacemakers;
  4. Epilepsy with recurrent seizures;
  5. Cognitively impaired patients will be excluded;
  6. Claustrophobia;
  7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
  8. Major depression and a history of psychotic disorders;
  9. Terminal diagnosis with life expectancy <=1 year.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: real-sham

Subjects will receive 10 sessions of real nTMS, 5 times a week for 2 weeks, followed by 10 sessions of sham nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS.

Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday).

For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level.

The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area.

Experimentell: sham-real

Subjects will receive 10 sessions of sham nTMS, 5 times a week for 2 weeks, followed by 10 sessions of real nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS.

Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday).

For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level.

The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Tinnitus Handicap Inventory (THI)
Tidsram: Week 0

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 0
Tinnitus Handicap Inventory (THI)
Tidsram: Week 3

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 3
Tinnitus Handicap Inventory (THI)
Tidsram: Week 6

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 6
Tinnitus Handicap Inventory (THI)
Tidsram: Week 7

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 7

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Tinnitus Functional Index (TFI)
Tidsram: Week 0

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 0
Tinnitus Functional Index (TFI)
Tidsram: Week 3

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 3
Tinnitus Functional Index (TFI)
Tidsram: Week 6

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 6
Tinnitus Functional Index (TFI)
Tidsram: Week 7

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 7
Tinnitus-Visual Analogue Scale (T-VAS)
Tidsram: Week 0

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 0
Tinnitus-Visual Analogue Scale (T-VAS)
Tidsram: Week 3

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 3
Tinnitus-Visual Analogue Scale (T-VAS)
Tidsram: Week 6

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 6
Tinnitus-Visual Analogue Scale (T-VAS)
Tidsram: Week 7

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 7

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Nicodemus Oey, MBBS, PhD, NUH

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2025

Primärt slutförande (Beräknad)

30 oktober 2027

Avslutad studie (Beräknad)

30 oktober 2027

Studieregistreringsdatum

Först inskickad

20 februari 2026

Först inskickad som uppfyllde QC-kriterierna

20 februari 2026

Första postat (Faktisk)

27 februari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 december 2025

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera